A Framework for Organizational Effectiveness in the Non-Profit Organization

None profit organizations are entrusted with societys most important functions educating minds, uplifting souls and protecting health and safety. Most research on management performance systems has focused on for profit organizations with less emphasis or research conducted in the none profit sector. Lately, however, the publics faith in these institutions has been seriously undermined by revelations of wrongdoing and mismanagement. Recent scandals in organizations such as United Way of America, the United Nations, Empire Blue Cross and the National Association for the Advancement of Colored People bring to light that the performance of none profits is shrouded behind a veil of secrecy lifted only when disasters occur. (Herzlinger, 1999) According to Herzlinger, four common problems manifest themselves in none profit organizations, which are being aggressively tackled in profit organizations. First is the problem of ineffective organizations, ones that do not accomplish their social missions. A second problem is inefficiency such as spending too much on fund raising and administration and devoting less than a majority of funds to a service. A third difficulty is that of private inurement, where individuals who control tax exempt organizations attain excessive benefits for themselves. A fourth problem is excessive risk and lack of accountability. These problems are readily associated with none profit organizations as they lack the self interest that comes with ownership ensuring managers do not receive excessive compensation, that the business accomplishes it goals efficiently, and that risks are appropriately evaluated. Second they often lack the competition that would force efficiency and finally they lack the ultimate barometer of business success, the profit measure. (1999

A Framework for Organizational Effectiveness in the Non-Profit Organization

None profit organizations are entrusted with societys most important functions educating minds, uplifting souls and protecting health and safety. Most research on management performance systems has focused on for profit organizations with less emphasis or research conducted in the none profit sector. Lately, however, the publics faith in these institutions has been seriously undermined by revelations of wrongdoing and mismanagement. Recent scandals in organizations such as United Way of America, the United Nations, Empire Blue Cross and the National Association for the Advancement of Colored People bring to light that the performance of none profits is shrouded behind a veil of secrecy lifted only when disasters occur. (Herzlinger, 1999) According to Herzlinger, four common problems manifest themselves in none profit organizations, which are being aggressively tackled in profit organizations. First is the problem of ineffective organizations, ones that do not accomplish their social missions. A second problem is inefficiency such as spending too much on fund raising and administration and devoting less than a majority of funds to a service. A third difficulty is that of private inurement, where individuals who control tax exempt organizations attain excessive benefits for themselves. A fourth problem is excessive risk and lack of accountability. These problems are readily associated with none profit organizations as they lack the self interest that comes with ownership ensuring managers do not receive excessive compensation, that the business accomplishes it goals efficiently, and that risks are appropriately evaluated. Second they often lack the competition that would force efficiency and finally they lack the ultimate barometer of business success, the profit measure. (1999

Pan-cancer pervasive upregulation of 3 ' UTR splicing drives tumourigenesis

10.1038/s41556-022-00913-zNATURE CELL BIOLOGY246928-

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

Global economic burden of unmet surgical need for appendicitis

Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US $92 492 million using approach 1 and$73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was $95 004 million using approach 1 and$75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially

Global economic burden of unmet surgical need for appendicitis

Background There is a substantial gap in provision of adequate surgical care in many low- and middle-income countries. This study aimed to identify the economic burden of unmet surgical need for the common condition of appendicitis. Methods Data on the incidence of appendicitis from 170 countries and two different approaches were used to estimate numbers of patients who do not receive surgery: as a fixed proportion of the total unmet surgical need per country (approach 1); and based on country income status (approach 2). Indirect costs with current levels of access and local quality, and those if quality were at the standards of high-income countries, were estimated. A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. Results Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. The economic burden of continuing current levels of access and local quality was US $92 492 million using approach 1 and$73 141 million using approach 2. The economic burden of not providing surgical care to the standards of high-income countries was $95 004 million using approach 1 and$75 666 million using approach 2. The largest share of these costs resulted from premature death (97.7 per cent) and lack of access (97.0 per cent) in contrast to lack of quality. Conclusion For a comparatively non-complex emergency condition such as appendicitis, increasing access to care should be prioritized. Although improving quality of care should not be neglected, increasing provision of care at current standards could reduce societal costs substantially